An interventional study of Experimental and Negative control in Periodontitis, Probiotics and Non Surgical Periodontal Therapy, sponsored by G. d'Annunzio University. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-04.
Sponsored by G. d'Annunzio University · Not applicable, Interventional, and Treatment
The goal of this randomized clinical trial is to test the effect orally administration of Probiotics based on Lactobacillus rhamnosus LR04 and Lactobacillus plantarum LP14 as adjuvant in people suffering from periodontitis stage II-III. The main questions it aims to answer are:
Partecipants in the test group will take the test probiotic for 90 days in adjunction of the routinary oral hygiene procedures.
Partecipants in the positive controlled group will take the placebo for 90 days in adjunction of the routinary oral hygiene procedures.
Partecipants in the negative control group will perform only the routinary oral hygiene procedures.
Researchers will compare 3 groups to see if orally administered probiotics based on L. rhamnosus and L. plantarum may hel in the reduction of periodontal indexes and of the periodontal pathogen bacteria.
The diagnosis of periodontitis passes through the recording of periodontal probing values on 6 sites for each periodontal element, the recording of clinical indices such as the percentage of bleeding sites and those with plaque, finally through the execution of a full-x-ray consisting of intraoral films that guarantee staging through the calculation of the loss of clinical attachment, corresponding to the loss of alveolar bone caused by the disease. The therapy of periodontitis is composed of several steps and begins with the control of the biofilm. This control is carried out with professional supragingival hygiene sessions followed by subgingival instrumentation of the periodontal pockets in order to remove the hard and soft deposits below the gingival margin, which would not otherwise be eliminated with the supragingival strategy alone. The response to mechanical therapy and the risk of relapses go hand in hand with the patient's response, his ability to maintain a good level of oral hygiene at home and to keep return appointments. In this sense, dental research has worked hard to develop additional aids to mechanical therapy to try to improve its performance. In the last decade in particular, the use of probiotics has found an increasingly wider field in periodontology, as they are based on the idea of enhancing the eubiosis ratios of the non-pathogenic flora in order to make the environment unfavorable for the proliferation of a pathogenic flora.
The present study aims to evaluate whether the quarterly oral administration of probiotics based on Lactobacillus plantarum LP14 and Lactobacillus rhamnosus LR04 can improve the response to non-surgical periodontal therapy of subgingival instrumentation in patients suffering from stage II-III periodontitis and complexity of grade A-B.
Primary objective To evaluate the adjuvant effect of probiotics based on Lactobacillus plantarum LP14 and Lactobacillus rhamnosus LR04 in non-surgical periodontal therapy.
Secondary objective Characterize the microbiological picture of patients with periodontitis with and without the aid of probiotics.
MATERIALS AND METHODS Three groups of volunteers of both sexes will be enrolled for the study without age restrictions.
Inclusion criteria Patients in the absence of other systemic pathologies reported in the medical history, smokers and non-smokers, non-drinkers, in the absence of previous or current administration of other sources of probiotics, capable of providing informed consent.
Exclusion criteria Subjects with a history of systemic diseases (diabetes, autoimmune diseases, inflammatory bowel diseases, neurodegenerative diseases), drinkers, who take or have taken probiotics in the last 3 months, unable to provide informed consent.
Minimum sample size Sample size calculation (Alpha = 0.05; Power = 95%) for 3 independent study groups, and a continuous primary endpoint. Sample size = Z2 (1-alpha/2) p (1-p) / d2 Where Z(1-alpha/2) is the standard variate corresponding to 1.96 at 5% type 1 error, p is the expected proportion in the population expressed in decimals based on previous studies and d is the confidence level decided by the researcher expressed in decimal. Regarding the primary outcome of Bleeding On Probing (BOP), the expected difference between the means was assumed to be 20%, therefore 20 patients per group are required, for a total of 60 patients. To these patients, the dropout percentage of 10% must be added, so the total is 70 patients.
T0 - BASELINE The first dental visit and the treatment plan will be carried out by Prof. Marco Dolci. The periodontal visit with the registration of the indices and the full-rx will be carried out by Prof. Marco Dolci.
Clinical indixes
The operational session will be organized as follows:
The same Biomolecular Diagnostic company will take care of collecting the samples via dedicated biological courier and will carry out the PCR analyzes in its laboratories.
At the end of the analyses, a copy of a unique identification code will be sent to the Experimenters so that they can access the report.
Placement of the patient in the test, positive and negative control groups
TEST: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste + probiotic in buccal sachet to be consumed once a day until the quarterly check-up.
POSITIVE CONTROL: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste + industrial placebo in buccal sachet to be consumed once a day until the quarterly check-up.
NEGATIVE CONTROL: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste.
The products (test and placebo) will be delivered to the patient at the end of the session in order to cover 3 months of administration.
T1 - AFTER 3 MONTHS FROM T0
Randomization The treatment that is due to the individual patient is kept in sequentially numbered, opaque and sealed envelopes (SNOSE Sequentially Numbered, Opaque, Sealed Envelopes). The products used for both the test and the controls will be supplied in anonymous tubes so that neither the patient nor the investigator will be aware of them.
Statistical analysis Proper statistical analysiswill be perfomed by the trusted statistical group.
1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.
This study's planned enrollment of 70 is above the median of 45 across 1,191 interventional studies indexed under Periodontitis.
Browse Periodontitis studies →G. d'Annunzio University is the lead sponsor of 62 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients who will be assigned to oral consumption of one stick of probiotics with L. plantarum and L. rhamnosus for 30 days, in adjucntion to routinary oral hygiene procedures.
Other: Experimental
Patients who will be assigned to oral consumption of one stick of placebo for 30 days, in adjucntion to routinary oral hygiene procedures.
Other: Positive control
Patients who will be assigned to routinary oral hygiene procedures esclusively.
Other: Negative control
Orally administred probiotics with L. plantarum and L. rhamnosus
Also known as: Orally administration of probiotics with L. plantarum and L. rhamnosus
Only routinary oral hygiene procedures
Also known as: Only routinary oral hygiene procedures
Orally administred placebo without probiotics
Also known as: Orally administred placebo without probiotics
Reduction of clinical periodontal indexes
Evaluation of clinical periodontal indexes, such as: bleeding on probing (BOP), periodontal pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), total number of pathological sites in %.
Time frame: From enrollement to the end of treatment at 3 months.
Reduction of periodontal pathogen bacteria amount.
Evaluation of the amount of periodontal pathogen bacteria such as: A. actinomycetemcomitans, P. gingivalis, P. intermedia and F. nucleatum
Time frame: From enrollement to the end of treatment at 3 months.
Plan to share: No — A decision regarding IPD sharing has not been made yet because a dedicated website is not available at the momente.
This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
G. d'Annunzio University